# Silexion Therapeutics (NASDAQ: SLXN)

> Silexion Therapeutics Corp. (NASDAQ: SLXN) is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) treatments for KRAS-driven cancers, including pancreatic cancer. Its lead candidate, SIL204, is being investigated in a Phase 2/3 clinical program for locally advanced pancreatic cancer.

Key facts:
- Exchange / ticker: NASDAQ: SLXN.
- Lead candidate: SIL204, an RNAi therapy being investigated in a Phase 2/3 clinical program for locally advanced pancreatic cancer.

## Pages
- [Overview](https://silexion.com/): company summary and clinical program
- [Our Science](https://silexion.com/science): RNAi and targeted delivery platform
- [Press Releases](https://silexion.com/press-releases): company announcements and corporate updates
- [Investor Relations](https://silexion.com/investors): filings, stock information, governance, presentations, and alerts
- [SEC Filings](https://silexion.com/investors/sec-filings): annual, quarterly, and current reports
- [Presentations & Events](https://silexion.com/investors/presentations): corporate presentations and investor events
- [Investor Alerts](https://silexion.com/investors/alerts): email updates for company news

## Latest press releases
- [Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences](https://silexion.com/press-releases/slxn-20260909-silexion-therapeutics-to-participate-in-september-2026-indus): 2026-09-09
- [Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://silexion.com/press-releases/slxn-20260814-silexion-therapeutics-reports-second-quarter-2026-financial): 2026-08-14
- [Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering](https://silexion.com/press-releases/slxn-20260812-silexion-therapeutics-announces-pricing-of-25-million-public): 2026-08-12
- [Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers](https://silexion.com/press-releases/slxn-20260804-silexion-therapeutics-reports-new-positive-preclinical-findi): 2026-08-04
- [Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center](https://silexion.com/press-releases/slxn-20260729-silexion-therapeutics-successfully-initiates-phase-23-clinic): 2026-07-29
- [Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer](https://silexion.com/press-releases/slxn-20260623-silexion-therapeutics-receives-approval-from-germanys-bfarm): 2026-06-23
- [Silexion Therapeutics to Attend BIO International Convention 2026](https://silexion.com/press-releases/slxn-20260616-silexion-therapeutics-to-attend-bio-international-convention): 2026-06-16
- [Silexion Therapeutics Announces 1-for-10 Reverse Share Split](https://silexion.com/press-releases/slxn-20260526-silexion-therapeutics-announces-1-for-10-reverse-share-split): 2026-05-26
- [Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://silexion.com/press-releases/slxn-20260518-silexion-therapeutics-reports-first-quarter-2026-financial-r): 2026-05-18
- [Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds](https://silexion.com/press-releases/slxn-20260515-silexion-therapeutics-announces-exercise-of-warrants-for-1-m): 2026-05-15
- [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer](https://silexion.com/press-releases/slxn-20260514-silexion-therapeutics-reports-positive-preliminary-immunothe): 2026-05-14
- [Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center](https://silexion.com/press-releases/slxn-20260513-silexion-therapeutics-announces-initiation-of-gmp-clinical-s): 2026-05-13
- [Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer](https://silexion.com/press-releases/slxn-20260428-silexion-therapeutics-announces-successful-submission-of-pha): 2026-04-28
- [Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer](https://silexion.com/press-releases/slxn-20260324-silexion-therapeutics-receives-approval-from-israeli-ministr): 2026-03-24
- [Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://silexion.com/press-releases/slxn-20260317-silexion-therapeutics-reports-fourth-quarter-and-full-year-2): 2026-03-17
- [Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting](https://silexion.com/press-releases/slxn-20260305-silexion-therapeutics-urges-shareholders-to-vote-ahead-of-ma): 2026-03-05
- [Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit](https://silexion.com/press-releases/slxn-20260121-silexion-therapeutics-to-attend-7th-annual-rnai-based-therap): 2026-01-21
- [Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026](https://silexion.com/press-releases/slxn-20260106-silexion-therapeutics-releases-ceo-letter-to-shareholders-hi): 2026-01-06
- [Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer](https://silexion.com/press-releases/slxn-20251216-silexion-therapeutics-announces-submission-of-phase-23-clini): 2025-12-16
- [Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer](https://silexion.com/press-releases/slxn-20251202-silexion-therapeutics-receives-positive-feedback-from-german): 2025-12-02

## Optional
- [Full text of this site](https://silexion.com/llms-full.txt)
- [Sitemap](https://silexion.com/sitemap.xml)